Endra Life Sciences Inc

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker